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Abstract 42 
Objectives: Olaparib is approved as maintenance therapy in patients with BRCA mutated platinum sensitive 43 
(PS) recurrent ovarian cancer (OC) after response to last platinum-based therapy. Few data are available 44 
regarding the use out of the registration trials and on response to further treatments after progression. 45 
Materials ad methods: In this non interventional, retrospective study, patients treated with olaparib in 13 46 
centers, according to the label, have been collected and analyzed. Primary objectives of the study is to 47 
describe effectiveness and safety of olaparib in a real world setting with a focus on post progression 48 
treatments and response. 49 
Results: 234 patients were analyzed. All patients were BRCA mutated and most of them had germline 50 
mutations. Around 50% of the patients received olaparib after 3 or more lines of platinum-based 51 
chemotherapy achieving a radiologic complete (CR) or partial response. 12.4% patients with stable disease 52 
were also included. Median PFS was 14.7 months (95% CI:12.6-18), with statistically longer PFS in patients 53 
with normal serum Ca125 at baseline, a CR after last platinum based therapy and that received olaparib after 54 
second platinum-based therapy. Median OS was not reached. Most frequent G3-G4 toxicity was anaemia 55 
(6%) with dose discontinuation and dose reduction in 11 (4.7%) and 49 (20.9%) of cases, respectively. 56 
Among 66 patients receiving further treatment after olaparib progression and evaluable for response, ORR 57 
was 22.2, 11.1% and 9.5% in patients with Platinum Free interval (PFI) of more than 12 months, between 6 58 
and 12 months and less than 6 months, respectively. 59 
Conclusions: Olaparib is effective and safe in real world setting. Data on post-progression treatments seem 60 
to suggest cross resistance with chemotherapy and need to be confirmed in larger studies because of the 61 
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Introduction  68 
Ovarian Cancer (OC) is the most lethal gynecological malignancy worldwide [1, 2]. Indeed, it is frequently 69 
diagnosed at an advanced stage and despite optimal debulking surgery and platinum based chemotherapy, 70 
about 70% of patients relapse [3]. Recurrent patients can be roughly divided in those that are not candidate to 71 
receive a platinum rechallenge and those seplatinum-sensitive (PS),that are candidate to receive platinum 72 
again [1, 4-6]. 73 
In the last years, new knowledge on OC biology showed that almost half of the High-Grade Ovarian Cancer 74 
shows an alteration of Homologous recombination (HR) that is a high fidelity DSBs DNA repair mechanism, 75 
active during cell replication [7, 8]. These alterations lead to HR Deficiency (HRD), causing a less preserved 76 
DNA integrity and a higher response to DNA damaging agents like platinum compounds [9]. Among these 77 
alterations, BRCA1 and 2 mutations account for 22.6% of mutations in HGSOCand are related to increased 78 
risk of breast cancer and OC and a younger age at diagnosis, with 2/3 present at germline level and 1/3 79 
somatic. The patients carrying these mutations are highly responsive to platinum and this biological 80 
characteristics have been exploited therapeutically with the use of PolyADP Ribose Polymerase Inhibitors 81 
(PARPIs), that historically act with a synthetic lethal mechanism, leading HRD cells to apoptosis [10, 11]. 82 
Indeed they inhibit PARPs, a family of enzymes that repair DNA Single strand Break (SSB) via Base 83 
Excision Repair (BER) and promote a conservative DNA repair facilitatingHR and inhibiting Non 84 
Homologous End Joining (NHEJ), a less conservative mechanism of repair[12, 13]. In vitro studies shows 85 
that BRCA1/2 mutated cell lines are really sensitive to cytotoxic activity of PARPIs and clinical trials 86 
confirmed that greatest benefit from PARPis is displayed in BRCA1/2 mutated patients, although an 87 
interesting activity was seen also in BRCA wild type OCs [12, 14]. 88 
Among these drugs, olaparib was the first in class drug to be developed and approved in OC. Olaparib is an 89 
oral inhibitor of PARP 1, PARP2 and PARP 3 [15, 16] that has been approved by EMA in 2014 as 90 
maintenance for patients with relapsed, platinum sensitive (with interval between last dose of platinum 91 
derivatives and progression longer than 6 months) BRCA-mutated (germline and/or somatic) HGSOC with 92 
complete or partial response (CR/PR) to last platinum-based chemotherapy [17]. This approval was based on 93 
Study 19, a randomized, placebo controlled phase II trial [18]. In this study 265 patients with PS recurrent 94 
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OC in response to last platinum based chemotherapy were randomized to receive Olaparib 400 mg twice a 95 
day or placebo as maintenance therapy. This study showed a significantly longer PFS for experimental arm 96 
(8.4 vs 4.8 months with HR of 0.35 P<0.001) with a greater benefit in BRCA (germline and somatic) 97 
mutated subgroup (11.2 vs 4.3 months HR 0.18 P<0.0001) and a trend toward a benefit in OS, with 15 98 
patients receiving the drug for over 6 years[14, 18-20]Study 19results that was confirmed by were confirmed 99 
by theandSOLO2 trial, an international, multicentre, phase III randomized, double blind, placebo controlled 100 
trial, that enrolled 295 BRCA mutated recurrent OC patients[21]. In this latter trial patients receiving 101 
olaparib maintenance therapy achieved an improvementThese patients, after response to last platinum based 102 
chemotherapy, were randomized 2:1 to Olaparibin a new formulation (300 mg tablets, twice daily) or 103 
placebo until toxicity or progression. Primary endpoint was reached with an improvement of 13.6 months in 104 
PFS (19.1 vs 5.5 months in placebo arms, HR 0·30 p<0·0001) [21, 22].  105 
In both Study 19 and SOLO2 trials olaparib showed a safe profile, being the most frequent adverse events 106 
nausea, fatigue, vomiting and diarrhea, above all Grade (G) 1-2 and the most frequent G3-G4 toxicity anemia 107 
(18%). Treatment compliance was high with around 20% of the patients decreasing the dose due to toxicity 108 
[21].  109 
Although these results have modified clinical practice in this setting, real world data on the use of PARPis 110 
are scarce, with short follow-up and small study populations [23-25], so there is the need to evaluate 111 
effectiveness efficacyand safety of olaparib in a real world setting, to understand if  the results obtained in 112 
the selected patients included in the trials can be generalized to a wider and less selected population and, 113 
particularly  if compliance to treatment is preserved also in everyday clinical practice[26, 27]. Moreover,we 114 
have few data in the literature on post progression treatment and response. 115 
MITO therefore has designed a multicentre non interventional retrospective study that analyzed data from 116 
patients treated with olaparib in the general clinical practice, with the aim to describe effectiveness and 117 
safety data of olaparib in a real life setting, with a focus on post progression treatment and outcome. 118 
 119 
 120 
  121 
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Materials and methods 122 
 123 
This is a non interventional, retrospective study conducted in 13 MITO (Multicenter Italian Trials in Ovarian 124 
cancer and gynecologic malignancies) centers. The study has been approved by the ethical committee. 125 
Archival data from consecutive patients treated with olaparib (400 mg, capsule formulation) according to the 126 
EMA labelfrom September 1
st
 2015 up to 31 May 2019 have been collected by the centers, centralized in the 127 
coordinating institution(Istituto Nazionale per la Cura dei Tumori IRCCS Fondazione “G. Pascale” Napoli) 128 
and analyzed. Patients included in clinical trials were excluded. 129 
Primary objectives of the study is to describe effectiveness and safety of olaparib in a real world setting. 130 
Effectiveness of olaparib maintenance treatment was described in terms of Overall Response Rate (ORR) 131 
according to RECIST 1.1 [28], Progression Free Survival (PFS), and Overall Survival (OS). Incidence of 132 
Adverse events (AEs), as well as dose reductions due to AEs were recorded. Also, post progression treatment 133 
and response were recorded and analyzed in all the patients experiencing a progression during olaparib 134 
therapy.  135 
Disease assessment was performed according to routine practice (every 3 months) and RECIST 1.1 response 136 
was calculated locally. No central review was performed. 137 
Centers reported  all AEs records, graded according to Common Terminology Criteria for Adverse events 138 
(CTCAE) version 5.0 [29]. 139 
 140 
Statistical analysis  141 
Baseline characteristics were analyzed according to descriptive statistics. Continuous variables were 142 
described with median values and interquartile range; categorical variables were described in terms of 143 
absolute numbers and proportion over the total number of patients analyzed.   144 
PFS  defined as time from first day of olaparib administration until disease progression (defined as objective 145 
radiological disease progression using modified RECIST version 1.1 or clinical progression) or death. 146 
Patients who did not experience disease progression were censored on the date of the last follow-up visit. OS 147 
was defined from first day of olaparib administration to death for any cause or the last follow up visit for 148 
living patients. PFS and OS curves were described according to the Kaplan Meier product-limit method and 149 
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compared with adjusted Log Rank test. Median follow-up was calculated according to the inverted Kaplan 150 
Meier technique [30]. 151 
HR and 95% confidence interval (CIs) were estimate with multivariable Cox models including number of 152 
lines, stage, residual disease at primary surgery, previous treatment with bevacizumab, age (continuous), 153 
mutational status, ECOG and RECIST1.1 Response [31]. 154 
All the analyses were performed with STATA 14 MP (StataCorp. 2015. Stata Statistical Software: Release 155 
14. College Station, TX: StataCorp LP.) 156 
 157 
  158 
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Results 159 
Patients characteristics 160 
Two hundreds and thirty-four patients were enrolled from 13 centers, treated from 13 June 2015 to 31 May 161 
2019, cutoff date. Main characteristics of patients  are showed in Table 1. Median age at diagnosis was 53,2 162 
(IQR 46.6-59.4) years. About 71% of patients had an ECOG PS of 0,while  24.8% of patients had an ECOG 163 
PS of 1 or 2; in 38,5%of the  patients comorbidities were reported. All patients were BRCA mutated. About 164 
70% of patients had a BRCA1 mutation, while 29.9%  carried a BRCA 2 mutation, 1 patient was both BRCA 165 
1 and BRCA 2 mutated. Most patients had germline BRCA mutation while 6.0% of patients had somatic 166 
mutation. Only 42.7% of the patients had familiar history of ovarian or breast cancer and 15.4% of the cases  167 
had personal history of breast cancer.  168 
Most patients (75.2%) had FIGO stage III OC at diagnosis, 91.9% of patients had an HGSOC histology, 169 
while the remaining patients had OC with other subtypes (above all high grade endometrioid cancer). More 170 
than half patients were optimally debulked at diagnosis (60.3%) and almost all patients were treated with a 171 
platinum doublet at diagnosis, being Carboplatin-Paclitaxel three weekly (48.3%) and Carboplatin-Paclitaxel 172 
three weekly with Bevacizumab (41.5%) the most administered regimens. Median initial Platinum Free 173 
Interval (time between the last cycle of platinum during first line and evidence of disease progression, 174 
PFI)after first line was18 (IQR 12-27.5) months. 175 
Patient characteristics before olaparib administration are summarized in table 2. 176 
Patients that received olaparib had a median PFI after last platinum therapy of 9.0 (5.0-14.2) months. In 177 
47.4% of the patients olaparib was administered after second platinum-based line. Nevertheless, 41.0% and 178 
11.5% of patients received olaparib after 3 and 4 or more lines of platinum based chemotherapy, 179 
respectively. As for platinum based regimens, 86.3% of patients received a platinum doublet before 180 
maintenance therapy with olaparib, while 10.3% of the patients received a platinum derivative alone. Most 181 
patients had a radiologic PR (45.3%) or CR (38.9%) to last platinum based therapy, but 12.4% patients 182 
received olaparib after a Stable disease (SD). 183 
 
[Digitare il testo] Pag. 10 
 
 184 
Treatment  effectiveness 185 
With a median follow up of 15.5 months (95% CI 13.0-18.2), 234 patients received at least one dose of 186 
olaparib. One hundred and twenty three patients were evaluable for radiologic response with 35 CR, 22 PR 187 
and an ORR of 46.3%. Among patients with SD after last platinum therapy, six patients out of 29 achieved a 188 
PR or CR per RECIST (20.7%). At time of analysis 150 patients have received olaparib for at least 6 months, 189 
85 patients for at least 12 months and 35 patients treated for more than 2 years. About 50% of the patients 190 
are still on treatment at time of the analysis. 191 
With 116 events recorded, median PFS (mPFS)  was 14.7 months (95% CI:12.60-18.03) (Figure 1). 192 
Explorative subgroups analysis have been performed (see Table 3 and Figure 2). Median PFS was 193 
statistically longer in patients with normal serum Ca125 at baseline (cut off 35 UI/ml) (25.5 months vs7.9 194 
months with and an adjusted HR of 2.5 (95% CI 1.5-4.3, p: 0.001). Also patients receiving olaparib after 195 
second platinum based had longer PFS compared to those treated in third and in later lines, with a mPFS of 196 
16.6, 15.5 and 8.2 months for patients treated in 2nd line, 3rd  line  and later lines [adjusted HR of 1.9 (95% 197 
CI 1.1-3.5, p:0.031) and of 2.5 (95% CI 1.3-4.8, p: 0.004), respectively]. Patients achieving a CR after last 198 
platinum based therapy had a statistically significant longer mPFS if compared with patients achieving a PR 199 
[(33.4 vs 10.4 months), HR of 3.0 (95% CI 1.6-5.8 p:0.001)], and a SD [(33.4 vs 9.2 months), HR of 2.7 200 
(95%CI 1.2-6.1, p: 0.017)], respectively. 201 
No difference in mPFS was recorded according to stage and residual disease at primary surgery, 202 
administration of Bevacizumab during first line treatment, ECOG PS, BRCA 1 or 2 status, age or previous 203 
familiar history of BC or OC. Median OS was not reached with only 32 events recorded (Figure 1). 204 
Dose adjustment and safety 205 
Two hundred and twenty nine patients received olaparib at the recommended starting dose of 400 mg b.i.d, 206 
while 5 patients received the drug at a reduced dose of 200 mg b.i.d since the beginning. Median treatment 207 
discontinuation was 11.6 months and reason for discontinuation was progression or death in 108 patients 208 
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(46.2%) and toxicity in 11 (4.7%) of cases. Dose adjustment was required in 49 (20.9%) patients  above all 209 
for hematologic toxicities (anaemia in 33% of dose adjustments). Most frequently recorded toxicities were 210 
nausea (35.7%) anaemia (35.7%) and fatigue (35.1%), above all G1 or 2. Most frequent G3-G4 toxicity was 211 
anaemia (6%) (See Table 4 for all G3-G4 AEs). 212 
There was no statistical difference in incidence of G3-G4 AEs according to interval between last cycle of 213 
chemotherapy and first dose of olaparib maintenance therapy or according to line of therapy (2nd line versus 214 
later line). There was no statistical difference in PFS between patients treated with recommended dose of 400 215 
mg bid and patients requiring a dose reduction (or treated with reduced dose since the beginning). 216 
 217 
Post progression treatments 218 
Among 110 patients with progressive disease, 2 patients received endocrine therapy and 86 patients received 219 
at least one further line of chemotherapy. Among these women, 25 had a PFI of more than 12 months, 39 a 220 
PFI between 6 and 12 months and 24 a PFI of less than 6 months. Sixty-six patients were evaluable for 221 
response.  222 
Response to post progression therapy is reported in Table 5. Eighteen (72%) patients with PFI of more than 223 
12 month wereevaluable for response. Among these, 14 cases were treated with a platinum based therapy, 224 
with 13 patients receiving platinum doublet and 1 patients receiving carboplatin as single agent. ORR was 225 
22.2% (1 CR; 3 RP; 7 SD, 7 PD). 226 
Among patients with PFI between 6 and 12 months, the most frequent treatment was a rechallenge with 227 
platinum derivatives (35.9%, 14 patients), although 64.1% of patients received other therapies (12 patients 228 
received trabectedin alone in the setting of MITO23 trial, 4 patients received trabectedin in combination with 229 
liposomal pegilated doxorubicin). Among patients of this group evaluable for response, ORR was 11.1% (3 230 
PR, 8SD; 16 PD). 231 
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Patients with PFI of less than 6 months received a monotherapy in the majority of the cases, being weekly 232 
paclitaxel and trabectedin  (9 and 4 patients respectively) the most frequently administered regimens. ORR 233 
was 9.5% (1 CR and 1 PR) with a PD in 76.2% of the cases.   234 
 
[Digitare il testo] Pag. 13 
 
Discussion  235 
This study analyzed 234  BRCA mutated recurrent patients with OC treated with olaparib as maintenance 236 
after a platinum based chemotherapy.  Median PFS was 14.7 months (95% CI:12.6-18), that is comparable to 237 
the data of the registration trials, and a safe toxicity profile was also observed in this real life setting. 238 
Interestingly patients progressed after olaparib and that were treated with chemotherapy had unexpected poor 239 
response rate of 22.2, 11.1% and 9.5% in patients with a PFI of more than 12 months, between 6 and 12 240 
months and less than 6 months, respectively. 241 
Our study is the first work that reports data on post progression treatment and response after maintenance 242 
therapy with olaparib, suggesting that RR is lower than expected. With the intrinsic limit of its retrospective 243 
nature, this finding shed a light on one of the upcoming urgent clinical research need, being olaparib 244 
maintenance therapy, a new standard also in first line treatment. 245 
We currently know that olaparib and other PARPi maintenance therapy improved PFS in registration 246 
randomized clinical trials in recurrent patients treated as maintenance  after response to platinum based 247 
chemotherapy. Namely, in Study 19 phase II trial patients receiving olaparib 400 mg twice a day as 248 
maintenance therapy had a longer PFS (8.4 vs 4.8 months in placebo arm with HR of 0.35 P<0.001) with a 249 
greater benefit in BRCA (germline and somatic) mutated subgroup (11.2 vs 4.3 months HR 0.18 P<0.0001) 250 
and a trend toward a benefit in OS, [14, 18-20]. These data were later confirmed by the SOLO2 trial [21], in 251 
which BRCA mutated patients receiving olaparib (300 mg tablets, twice daily)  maintenance therapy had 252 
significant benefit in PFS [21, 22]. After these results olaparib has been rapidly introduced in everyday 253 
practice, modifying treatment algorithms. Nevertheless in SOLO2 and Study 19 trial, as usually in all 254 
registration trials [14, 21], olaparib was administered to very selected patients from highly experienced 255 
providers with very straight rules, timelines and schedules per protocol. This improved PFS obtained in an 256 
ideal setting needs external validity in a less selected population.  257 
Real world studies could be useful as a ”measure in understanding health care data collected under real life 258 
practice circumstances” (European Forum “Relative Effectiveness” Working group) [32], and the results can 259 
help defining if drugs are effective also in real world setting.with heterogeneous populations in centers with 260 
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representative providers and outside straight rules of protocols. Moreover defining cost-effectiveness of new 261 
drugs could be easier if results from clinical trials are straightened by real world studies. 262 
Few results from olaparib real world use have been reported, with short follow up [25] or small population 263 
[33], lacking essential clinical information like BRCA status [23] and focusing above all on safety. 264 
This study is the first real world experience published in extenso including only BRCA mutated patients with 265 
OC treated according to EMA label with olaparib maintenance therapy after platinum based therapy. Indeed, 266 
as a result of a real world setting, 24.8% of our patients had ad ECOG PS of more than 0 and 38.5% had 267 
registered comorbidities. Our study, as in the registration trials,  includes patients  receiving olaparib after at 268 
least second line of platinum based therapy, with several cases treated after 3 or 4 lines of chemotherapy. 269 
In our study median PFS was 14.7 months and was 14.7 months. This result is is slightly lower than in the 270 
SOLO2 trial (19.3 months) [21] (Table 6). This difference could be explained by the less selected population 271 
including also some cases treated after a SD at the last platinum received.Subgroup analyses identified 272 
patients with a longer PFS providing information that could be useful in patient consenting clarifying them 273 
the  expectations of patients in this setting. Indeed our analyses suggest that patients achieving a CR to last 274 
platinum therapy and with low Ca 125 at baseline, have a better PFS when treated with olaparibin terms of 275 
PFS, identifying a population that probably includes long responders to olaparib. This results are consistent 276 
with data  published by other groups [34, 35], although the prognostic role of Ca 125  has never been 277 
reported in this setting and, if confirmed, could be an easy tool for clinicians to predict duration of treatment 278 
with olaparib. Ca 125 data need also to be taken into account when indirectly comparing  efficacy in trials 279 
with different PARPi; in fact some registration trials included only patients with normalized Ca 125 [36]. 280 
Although SOLO2 has demonstrated that the benefit of olaparib is evident independently from the number of 281 
previous line, we show that patients treated after 3 or 4 chemotherapy lines have significantly shorter PFS. 282 
We believe that this information can be useful for clinicians and patients when deciding the therapy, 283 
particularly where alternative regimens are available. 284 
In our series a small subgroup of patients with SD to last platinum based therapy was treated with olaparib 285 
achieving a ORR of 20.7%. Although this group of patients is small these data suggested an interesting 286 
activity also in this setting. 287 
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As for safety, data on AEs and dose reduction do not differ from results of SOLO 2 trial, confirming that 288 
olaparib is a manageable drug also in everyday practice in a less fit population. Moreover dose reduction was 289 
recorded in  20.9% of patients (a result similar to SOLO2 trial) and does not seems to worsen outcome in our 290 
population. 291 
We believe that an interesting data from our  real world study is the post progression treatment efficacy in 292 
this setting. In fact, we found that ORR to chemotherapy in patients evaluable for response is lower than 293 
expected according to the PFI [37, 38].  In particular we found an ORR of only 22.2% in  patients progressed 294 
after a longer olaparib therapy, treated with platinum again after a PFI of more than 12 months. Due to the 295 
fact that about 50% of the patients are still on treatment, these data will need further update and have to be 296 
considered preliminary. Also, the retrospective nature of the trial that is based on self-reported response rate 297 
require that our conclusions need to be confirmed. Nonetheless, we believe that this observation will prompt 298 
further research in the field exploring cross resistance between PARPi and chemo, and if confirmed in 299 
further studies, might have a significant impact on our clinical decisions.  300 
The cross resistance suggested in our study has been demonstrated in preclinical models [39], and could play 301 
a role also in the clinic. In fact, although in the registration trials it has been shown that the time to second 302 
progression is prolonged in the arms treated with PARPis, the response to chemotherapy has not been 303 
described and data may be important in the selection of the drugs to be used in clinical practice, with more 304 
sequence studies needed in the future. These data may have also have a potential impact on the strategy  of 305 
PARPIs after PARPIs that is currently under investigation (NCT03106987, OReO study). 306 
Our results seems to beare in contrast with a retrospective study published by Kaye and colleagues [40] that 307 
showed an ORR of 36% in 67 patients that progressed to olaparib and were treated with chemotherapy and 308 
an ORR of 40% in 48 patients receiving a platinum derivative. Nevertheless they analyzed both platinum 309 
sensitive and resistant patients that received olaparib not only as maintenance therapy but also as 310 
monotherapy, with a median interval from start of olaparib and subsequent line of only 7.4 months making 311 
the comparison between the two studies difficult due to different populations[40].  312 
In conclusion we found that olaparib given in a real life setting of less selected patients is active and well 313 
tolerated. Patients in CR and with normal Ca125 have longer PFS. Nevertheless Further studies will be 314 
needed to clarify if these easy clinical parameters can help to identify the population of long responders cases 315 
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that have been described with all the PARPi.we found lower response rates than expected according to PFI in 316 
patients treated with chemotherapy after olaparib progression. These data, although provocative, need to be 317 
confirmed in further studies investigating this important aspect also in the first line scenario, and adding 318 
translational studies evaluating the biological meaning of cross resistance between PARPi and 319 
chemotherapy. 320 
  321 
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 346 
Table 1: patients characteristics at diagnosis of ovarian cancer 347 
Characteristic of patients N=234 (%) 
Age ,years   
 Median, IQR  53.2 (46.6-59.4) 
ECOG PS, n (%)   
 0  167  (71.4) 
 1  48  (20.5) 
 2  10  (4.3) 
 Unknowm 9  (3.8) 
Comorbidities, n (%)  
 Yes 90  (38.5) 
 No 123 (52.5) 
Unknown 21  (9.0) 
Familiar history for Breast or Ovarian cancer, n (%)  
Yes 100  (42.7) 
No  118  (50.4) 
Unknown 16  (6.8) 
Personal history of Breast cancer, n (%)  
Yes  36  (15.4) 
No 179  (76.5) 
Unknown 19  (8.1) 
BRCA status, n (%)   
BRCA 1 mutation 163  (69.7) 
BRCA 2 mutation 70  (29.9) 
BRCA 1 and BRCA 2 mutation 1 (0.4) 
Type of mutation, n (%)   
Germline 153 (65.4) 
Somatic 14 (6.0) 
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Unknown 67 (28.6) 
Stage (FIGO) at diagnosis, n (%)   
 I-II 27 (11.5) 
 III 176 (75.2) 
 IV  25 (10.7) 
Unknown 6 (2.6) 
Histology, n (%)   
 Serous 215 (91.9) 
 Endometrioid 14 (6.0) 
 Clear cell 2 (0.9) 
 Mixed 1 (0.4) 
 Transitional 2  (0.9) 
Residual, n (%)   
 None 141 (60.3) 
 ≤ 1 cm 41 (17.5) 
 > 1 cm 41 (17.5) 
 Unknown 11 (4.7) 
 Fist line treatment, n (%)   
 Carboplatin- Paclitaxel three weekly+ Bevacizumab 97 (41.5) 
 Carboplatin Single agent 2 (0.9) 
 Carboplatin- Paclitaxel three weekly 113 (48.3) 
 Carbopltin Paclitaxel weekly 17 (7.3) 
 Others  5 (2.1) 
 PFI after first line,months   
 Median, IQR 18.0  (12.0-27.5) 
 348 
  349 
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Table 2: patients characteristics at time of olaparib administration 350 
Characteristic of patients N=234 (%) 
Number of platinum based lines pre olaparib   
2 111  (47.4) 
3-4 96  (41) 
>4 27  (11.5) 
PFI before last platinum based therapy(months)   
Median, IQR 9  (5-14.2) 
Platinum based therapy before olaparib   
Platinum combo 202  (86.3) 
Platinum single agent 24  (10.3) 
Other 8  (3.4) 
Radiologic response to last platinum based therapy   
Complete response 91  (38.9) 
Partial response 106  (45.3) 
Stable Disease 29  (12.4) 
Progressive disease 1    (0.4) 
Unknown  7    (3.0) 
Ca125 before olaparib administration   
≤35 UI/ml 138  (59.0) 
>35 UI/ml 51   (21.8) 
Unknown  45   (19.2) 
351 
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Table 3: : Exploratory subgroup analysis of Progression-free Survival 352 
 HR p 95%CI 
Ca 125     
Low vs high 2.5 0.001      1.5-4-3    
Number of previous lines    
1 vs 2 previous lines 1.9 0.031 1.1-3.5 
1 vs >2 previous lines 2.5 0.004 1.3-4.8 
RECIST response to last platinum based therapy 
CR vs PR 3.1 0.001 1.6-5.8 
CR vs SD or PD 2.7 0.017 1.2-6.1 
FIGO Stage at diagnosis    
I-II vs III 1.0 0.11    0.5-2.3 
I-II vs IV 1.1 0.25 0.4-3-0 
Residual disease     
R=0 vs R≠0 1.5 0.117 0.9-2.4 
Previous treatment with bevacizumab    
Yes vs not 1.15 0.641 0.6-2.1 
BRCA status    
BRCA1 vs BRCA2 mutation 0.7 0.165 0.4-1.2 
Age    
Old vs young 1 0.169 1.0-1.0 
ECOG PS    
0 vs 1 1.6 0.139 0.9-3.0 
0 vs 2 1.6 0.289 0.6-4.0 
 353 
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 354 
Table 4: recorded G3-G4 AEs 355 
Adverse event G3-G4 N=234 (%) 
Nausea  8  (3.4) 
Fatigue 3  (1.3) 
Anemia 13  (5.6) 
Thrombocytopenia 5 (2.1) 
Leucopenia or Neutropenia  4 (1.7) 
Abdominalpain 1 (0.4) 
Vomiting 2  (0.9) 
MDS  1  (0.4) 
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 365 
Table 5: Response to chemotherapy in patients treated after progression to olaparib. 366 
Platinum free interval CR PR SD PD 
PFI< 6mm 1 (4.8) 1(4.8) 3 (14.3) 16 (76.2)  
PFI: 6-12 mm 0  3 (11.1) 8 (29.6) 16 (59.3) 
PFI >12 mm 1 (5.6) 3 (16.7) 7 (38.9) 7 (38.9) 
  367 
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Table 6:table comparing results from SOLO2 Trial and this real world study. 368 
 SOLO2 MITO Real life study 
PFS 19.1 months 14.7 months 
ORR 30 (41.1%) 57(46.3%) 
Dose reduction 49 (25%) 49 (20.9%) 
Dose discontinuation 21 (11%) 11 (4.7%) 
 369 
  370 
 





Figure 1: With a median follow up of 15.5 months (95% CI 13.0-18.2), median PFS was 14.7 months (Figure 374 
1a) while median OS was not reached (Figure 1b). 375 
 376 
 377 
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 379 
Figure 2: Median PFS according to serum Ca125 at baseline (cut off 35 UI/ml, Figure 2a), number of 380 
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